We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Addus HomeCare (ADUS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Addus HomeCare is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Addus HomeCare is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ADUS' full-year earnings has moved 4.5% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ADUS has moved about 6% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0%. This means that Addus HomeCare is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) . The stock has returned 2.3% year-to-date.
In Arcutis Biotherapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 14.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Addus HomeCare belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 18 individual companies and currently sits at #74 in the Zacks Industry Rank. This group has gained an average of 17.6% so far this year, so ADUS is slightly underperforming its industry in this area.
On the other hand, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 512-stock industry is currently ranked #72. The industry has moved -9.8% year to date.
Addus HomeCare and Arcutis Biotherapeutics, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Are Medical Stocks Lagging Addus HomeCare (ADUS) This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Addus HomeCare (ADUS - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Addus HomeCare is a member of the Medical sector. This group includes 1010 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Addus HomeCare is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ADUS' full-year earnings has moved 4.5% higher within the past quarter. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
According to our latest data, ADUS has moved about 6% on a year-to-date basis. At the same time, Medical stocks have gained an average of 0%. This means that Addus HomeCare is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Arcutis Biotherapeutics, Inc. (ARQT - Free Report) . The stock has returned 2.3% year-to-date.
In Arcutis Biotherapeutics, Inc.'s case, the consensus EPS estimate for the current year increased 14.2% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
To break things down more, Addus HomeCare belongs to the Medical - Outpatient and Home Healthcare industry, a group that includes 18 individual companies and currently sits at #74 in the Zacks Industry Rank. This group has gained an average of 17.6% so far this year, so ADUS is slightly underperforming its industry in this area.
On the other hand, Arcutis Biotherapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry. This 512-stock industry is currently ranked #72. The industry has moved -9.8% year to date.
Addus HomeCare and Arcutis Biotherapeutics, Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.